Labcorp HoldingsLH +1.93%79 Days Payable is 27.78 as of Mar. 2026, which is 1% below its 10-year median of 28.05. GuruFocus rates LH with a GF Score™ of 79/100 and a GF Value™ of $271.46 (Fairly Valued). The stock has 6 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Labcorp Holdings ranks worse than 83.77% on this metric.
The historical rank and industry rank for Labcorp Holdings's Days Payable or its related term are showing as below:
LH'
s Days Payable Range Over the Past 10 Years
Min: 25.7 Med: 28.05 Max: 34.85
Current: 26.95
During the past 13 years, Labcorp Holdings's highest Days Payable was 34.85. The lowest was 25.70. And the median was 28.05.
LH's Days Payable is ranked worse than 83.77% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs LH: 26.95
Labcorp Holdings's Days Payable
declined
from Mar. 2025 (30.33) to Mar. 2026 (27.78).
It may suggest that Labcorp Holdingsaccelerated paying its suppliers.
Labcorp Holdings Days Payable Related Terms
Labcorp Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Labcorp Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Labcorp Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Labcorp Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (LH) has a Days Payable of 27.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Labcorp Holdings and its competitors. This is near median its historical median of 28.05. Over the past decade, Labcorp Holdings' Days Payable has ranged from 25.70 to 34.85. According to the industry distribution chart, Labcorp Holdings ranks #160 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 83.8%.
Is Labcorp Holdings' Days Payable too high?
Labcorp Holdings' current Days Payable of 27.78 is near median its 10-year median of 28.05. Over the past 10 years, this metric has ranged from a low of 25.70 to a high of 34.85. The Medical Diagnostics & Research industry median Days Payable is 68.87. Labcorp Holdings' value of 27.78 is 59.7% below this industry median. Based on the distribution chart, Labcorp Holdings ranks #160 out of 191 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Labcorp Holdings has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' Days Payable compare to DGX and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #160 out of 191 companies for Days Payable. This places Labcorp Holdings in the lower half of its industry. The industry median Days Payable is 68.87. Labcorp Holdings' value of 27.78 is 59.7% below this benchmark. Historically, Labcorp Holdings' own Days Payable has ranged from 25.70 to 34.85 over the past decade. While the company's 10-year median is 28.05 vs. the industry median of 68.87, Labcorp Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current Days Payable of 27.78 is 59.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current Days Payable is 27.78, which is near median its own 10-year median of 28.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LH) is currently considered Fairly Valued. The stock's GF Value™ is $271.46, compared to a current price of $271.47 — trading 0% above its estimated fair value. The current Days Payable is 27.78, which is near median its 10-year median of 28.05 and 59.7% below the Medical Diagnostics & Research industry median of 68.87. Labcorp Holdings' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Labcorp Holdings (LH), the current Days Payable is 27.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LH) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $271.47 is trading 0% above its estimated GF Value™ of $271.46.
GuruFocus considers Labcorp Holdings to be Fairly Valued.
Key valuation signals for LH:
Days Payable: 27.78 (near median its 10-year median of 28.05)
GF Value™: $271.46 vs. price of $271.47 (0% above fair value)
Industry Position: 59.7% below the Medical Diagnostics & Research median (#160 of 191)
No single metric tells the full story. See the LH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
79GF Score
Get the complete analysis for LH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LH has been successfully added to your 
